分子诊断公司BillionToOne, Inc.（股票代码：BLLN）今日在纳斯达克首次公开交易，盘中大涨66.67%，引起市场广泛关注。
据悉，BillionToOne的股票开盘价为每股100美元，较60美元的发行价大幅上涨66.7%。公司此次IPO发行了456万股股票，共募集资金2.731亿美元。值得注意的是，BillionToOne最初计划发行385万股，每股价格区间为49美元至55美元，但最终定价高于预期区间。
总部位于加利福尼亚州门洛帕克市的BillionToOne主要开发分子诊断测试，包括针对各种疾病的无创产前筛查和液体活检。公司近期财务表现亮眼，截至6月30日的六个月内，收入同比激增82%，达到1.255亿美元，净亏损缩小至420万美元。此次IPO由摩根大通、派珀桑德勒、杰富瑞和威廉布莱尔担任联合簿记管理人。BillionToOne的强劲debut表明投资者对其业务前景及生物科技行业整体保持乐观态度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.